VIR at a discount
VIR has a couple of interesting products testing in the pipeline.
The one that caused the spike in Jan is for hepatitis B treatment.
And the selloff today is caused by the pause in the enrollment of late-stage trial testing of their Covid19 antibody.
So it seems it is safe to assume that it will return above previous resistance of 53. With 80's as a first target, and then, potentially, to ATH.
The one that caused the spike in Jan is for hepatitis B treatment.
And the selloff today is caused by the pause in the enrollment of late-stage trial testing of their Covid19 antibody.
So it seems it is safe to assume that it will return above previous resistance of 53. With 80's as a first target, and then, potentially, to ATH.
註釋
Nice opening todayNot taking profit, expecting higher
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。